CSL Shares Fall To Lowest Level In Years – What Is Driving The Price Action?

CSL shares (ASX: CSL) closed at A$138 today, marking an eight-year low and capping a brutal 12-month decline that has seen the biotechnology giant lose nearly half its market value amid a cascade of earnings downgrades, restructuring charges, and strategic uncertainty.

The CSL share price fell a further 2.23% to A$138, closing at the session low and extending year-to-date losses to 19.75%. On a rolling 12-month basis, CSL shares have now collapsed 44.29%, erasing billions in shareholder wealth and dragging the share price to levels last seen in 2018. The company, once regarded as one of the ASX’s most reliable defensive growth stocks, has badly underperformed the broader ASX 200 index over the past two years, with momentum remaining firmly negative through early 2026.

Markets have been unforgiving since late 2025, when a series of profit warnings and operational missteps shattered confidence in what had been a perennial compounder. The share price has fallen through multiple technical support levels, with each bounce attempt met by fresh selling as institutional holders reassess the risk-reward profile of a business now guiding for only mid-single-digit growth.

What Is Behind The Move?

The roots of CSL’s current malaise trace back to the company’s full-year 2025 results on 18 August 2025, when management unveiled a sweeping global transformation program alongside otherwise solid backward-looking numbers. While fiscal 2025 delivered approximately 5% revenue growth and 17% net profit growth in US dollar terms, CSL simultaneously announced plans to cut around 3,000 jobs rationalise underperforming plasma collection centres, and consolidate research and development sites from 11 to six. The program carried one-off restructuring costs of between US$700 million and US$770 million, all to be expensed in fiscal 2026.

The scale of the overhaul signalled that CSL’s cost base and operational footprint had expanded beyond optimal levels, requiring painful near-term surgery in exchange for promised medium-term margin gains. Markets initially took the news in stride, but sentiment deteriorated sharply when management slashed fiscal 2026 guidance at the company’s annual general meeting on 28 October 2025.

That AGM proved to be the inflection point. CSL cut its fiscal 2026 revenue growth forecast from 4–5% to just 2–3%, and lowered net profit after tax and amortisation growth guidance from 7–10% to 4–7%. More troubling still, the company revised its medium-term outlook for fiscal years 2027 and 2028, reducing expected NPAT growth from low-teens to high-single digits, well below the double-digit expansion rates that had underpinned CSL’s premium valuation for more than a decade.

Management attributed the downgrade to sharply declining influenza vaccination rates in the United States, which pressured the Seqirus vaccines division, as well as slower-than-anticipated margin recovery in the core CSL Behring plasma business amid pricing and competitive headwinds. The stock fell approximately 14% on the day of the AGM, plunging to a six-year low and triggering a wave of analyst downgrades.

When CSL reported its half-year fiscal 2026 results a few weeks ago (24 February 2026), the damage was laid bare. Statutory net profit after tax collapsed 81%, driven largely by the restructuring charges flagged six months earlier. Excluding those one-off items, underlying revenue grew roughly 4% and underlying NPATA rose about 7%, precisely in line with the downgraded guidance, but offering no positive surprise to arrest the share price slide. Management reaffirmed full-year fiscal 2026 guidance and noted that around 60% of targeted cost savings had already been achieved, but markets focused on the headline profit collapse and the confirmation that fiscal 2026 would be a “reset year” with elevated costs and anaemic top-line growth.

The company’s Seqirus vaccines unit has emerged as a particular source of concern. Internal forecasts now incorporate a roughly 15% medium-term decline in flu vaccine revenues, reflecting structural headwinds in vaccination rates. That deterioration has also delayed any potential spin-off or demerger of the division, removing a near-term catalyst that some investors had hoped would unlock value.

Against this backdrop, CSL has continued to deploy capital aggressively. On 18 November 2025, the company announced plans to invest approximately US$1.5 billion over five years in new US manufacturing capacity for plasma-derived therapies, on top of more than US$3 billion already invested in US operations since 2018. CSL has also authorised a share buyback of around A$750 million, with significant capacity still outstanding, a signal that the board believes the current share price undervalues the business.

What Next For CSL?

Analyst sentiment on CSL remains mixed, with clear battle lines between the bulls and bears here.

Bears argue that the company has transitioned from a perennial compounder to a low-growth, capital-intensive business caught in a messy multi-year restructure, with returns on incremental capital now structurally lower than in the past. The combination of heavy capex, large restructuring costs, and only mid-single-digit near-term growth has led some commentators to question whether CSL can generate risk-adjusted returns that justify its share price, even after the sharp sell-off.

Bulls counter that CSL’s dominant position in global plasma collection, which is a business with high barriers to entry and long-duration demand, remains intact and that the current valuation represents a once-in-a-decade opportunity. Multiple broker notes suggest the stock is trading at its cheapest valuation on a price-to-earnings basis in roughly 14 years, with some target prices implying 30% to 35% upside if the company merely executes on its revised, lower guidance. Proponents of this view point to ongoing buybacks and continued investment in core plasma infrastructure as evidence that management and the board have conviction in the intrinsic value of the business.

The medium-term outlook hinges on the execution of the transformation program and realisation of promised cost savings; stabilisation and potential recovery in the Seqirus vaccines business; and evidence that the October 2025 guidance reset has finally “cleared the decks” of negative surprises. Any further downgrade would likely trigger another leg lower in the share price, while a clean fiscal 2026 result and credible fiscal 2027 guidance could catalyse a sharp rebound from deeply oversold levels.

CSL’s fall from grace has been swift and severe, transforming a once-bulletproof defensive growth stock into a polarising turnaround story that has tested the resolve of even the most patient long-term holders. Whether the current price represents capitulation or a value trap will be told in time, but for now, the bears are firmly in charge.